New York state-based Nutrition 21, a developer and marketer of chromium, selenium and omega-3 fish oil, said the scientific advisory board will provide guidance on research and future product development. The scientific advisory board is designed to comprise physicians and researchers with expertise in the therapeutic areas targeted by Nutrition 21's products. The company told NutraIngredients-USA in February that by the end of Nutrition 21's fiscal year in June 2007, it expects to have five branded product lines in national distribution - addressing pre-diabetes, diabetes, cardiovascular health, arthritis/joint health, and HIV. Nutrition 21 previously used its science portfolio to support branded ingredient Chromax's use in supplements. However, the company has opted for a change in direction and invested heavily in promoting Chromax directly as a finished supplement product through food, drug and mass retail outlets. "The formation of this board will help ensure that Nutrition 21 is at the forefront of new scientific advances," said Nutrition 21 CEO and president Paul Intlekofer. "This is another milestone in our continued growth and development as company committed to providing quality products backed by research." The members of the Scientific Advisory Board are:
Dr. Robert Golden, dean of the School of Medicine and Public Health, University of Wisconsin;
Dr. Louis Ignarro, professor of Pharmacology in the Department of Molecular and Medical Pharmacology, UCLA School of Medicine;
Dr. Francine Kaufman, head of the Center for Endocrinology, Diabetes and Metabolism at Children's Hospital Los Angeles;
Dr. Ron Krauss, director of Atherosclerosis Research at the Children's Hospital Oakland Research Institute.
"Each of these distinguished members represents expertise and leadership in their respective areas and we are honored to have them be a part of our scientific advisory board," said Intlekofer.